Ian C. P. Smith

Active 1965–2025

88
Papers
30,187
Citations
77
h-index
85
i10-index

Citations

Citations per year for Ian C. P. Smith1964: 1 citations1969: 1 citations1971: 1 citations1972: 17 citations1973: 14 citations1974: 18 citations1975: 20 citations1976: 37 citations1977: 43 citations1978: 52 citations1979: 30 citations1980: 63 citations1981: 44 citations1982: 32 citations1983: 49 citations1984: 43 citations1985: 25 citations1986: 33 citations1987: 30 citations1988: 16 citations1989: 26 citations1990: 49 citations1991: 24 citations1992: 20 citations1993: 33 citations1994: 44 citations1995: 37 citations1996: 33 citations1997: 38 citations1998: 48 citations1999: 52 citations2000: 37 citations2001: 57 citations2002: 71 citations2003: 70 citations2004: 84 citations2005: 68 citations2006: 72 citations2007: 66 citations2008: 61 citations2009: 48 citations2010: 47 citations2011: 48 citations2012: 44 citations2013: 50 citations2014: 58 citations2015: 138 citations2016: 222 citations2017: 288 citations2018: 437 citations2019: 969 citations2020: 1,204 citations2021: 1,134 citations2022: 1,016 citations2023: 775 citations2024: 1,059 citations2025: 574 citations2026: 37 citations1965–1968: no citations, so these years are not shown1970: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,938 citing papers, 28.3% of this breakdownChina: 1,346 citing papers, 9.7% of this breakdownUnited Kingdom: 929 citing papers, 6.7% of this breakdownGermany: 863 citing papers, 6.2% of this breakdownCanada: 576 citing papers, 4.1% of this breakdownItaly: 484 citing papers, 3.5% of this breakdownFrance: 458 citing papers, 3.3% of this breakdownSpain: 388 citing papers, 2.8% of this breakdownNetherlands: 370 citing papers, 2.6% of this breakdownJapan: 363 citing papers, 2.6% of this breakdownSwitzerland: 347 citing papers, 2.5% of this breakdownAustralia: 337 citing papers, 2.4% of this breakdown
0%28.3%Other 25.3%

Fields

  • Biochemistry, Genetics and Molecular Biology47%
  • Medicine33%
  • Computer Science6%
  • Engineering3.7%
  • Immunology and Microbiology2.9%
  • Neuroscience1.7%
  • Other5.7%

Topics

  • CRISPR and Genetic Engineering6.2%
  • Advanced Breast Cancer Therapies3.3%
  • Computational Drug Discovery Methods2.5%
  • RNA and protein synthesis mechanisms2%
  • Breast Cancer Treatment Studies1.9%
  • Bioinformatics and Genomic Networks1.9%
  • Other82.2%

Coauthors

All papers

Open in search
  1. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

    Authors: , , , , , , , , , , , , - Nature Biotechnology 2016 cited by 4,983

  2. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anita Vrcic, Corey Flynn, Jacqueline Rosains, David Y. Takeda, Roger Hu, Desiree Davison, Justin Lamb, Kristin Ardlie, Larson Hogstrom, Peyton Greenside, Nathanael S. Gray, Paul A. Clemons, Serena J. Silver, Xiaoyun Wu, Wen‐Ning Zhao, Willis Read-Button, Xiaohua Wu, Stephen J. Haggarty, Lucienne Ronco, Jesse S. Boehm, Stuart L. Schreiber, John G. Doench, Joshua A. Bittker, David E. Root, Bang Wong, Todd R. Golub - Cell 2017 cited by 3,788

  3. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 1,717

  4. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 1,656

  5. Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation

    Authors: , , , , , , , , , - Nature Biotechnology 2014 cited by 1,722

  6. Data-analysis strategies for image-based cell profiling

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Methods 2017 cited by 790

  7. Methodological consensus on clinical proton MRS of the brain: Review and recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dieter J. Meyerhoff, Carolyn E. Mountford, Paul G. Mullins, James B. Murdoch, Sarah J. Nelson, Ralph Noeske, Gülin Öz, Julie W. Pan, Andrew C. Peet, Harish Poptani, Stefan Posse, Eva‐Maria Ratai, Nouha Salibi, Tom W. J. Scheenen, Ian C. P. Smith, Brian J. Soher, Ivan Tkáč, Daniel B. Vigneron, Franklyn A. Howe - Magnetic Resonance in Medicine 2019 cited by 489

  8. Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity

    Authors: , , , , , , , - Frontiers in Physiology 2018 cited by 305

  9. Clinical Proton MR Spectroscopy in Central Nervous System Disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Małgorzata Marjańska, Andrew A. Maudsley, Dieter J. Meyerhoff, Carolyn E. Mountford, Sarah J. Nelson, M. Necmettin Pamir, Jullie W. Pan, Andrew C. Peet, Harish Poptani, Stefan Posse, Petra J. W. Pouwels, Eva‐Maria Ratai, Brian D. Ross, Tom W. J. Scheenen, Christian Schuster, Ian C. P. Smith, Brian J. Soher, Ivan Tkáč, Daniel B. Vigneron, Risto A. Kauppinen, For the MRS Consensus Group - Radiology 2014 cited by 666

  10. Implementation and relevance of FAIR data principles in biopharmaceutical R&D

    Authors: , , , , , , , , , , , , , , , , , - Drug Discovery Today 2019 cited by 165

  11. Nonlocalized postactivation performance enhancement (PAPE) effects in trained athletes: a pilot study

    Authors: , , , , , , - Applied Physiology Nutrition and Metabolism 2017 cited by 173

  12. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

    Authors: , , , , , , , , , , , - The Lancet Oncology 2012 cited by 657

  13. A High-Fat High-Sucrose Diet Rapidly Alters Muscle Integrity, Inflammation and Gut Microbiota in Male Rats

    Authors: , , , , , , , - Scientific Reports 2016 cited by 123

  14. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map

    Authors: , , , , , , , , , , - PLoS Biology 2017 cited by 178

  15. A Layered Hybrid Perovskite Solar‐Cell Absorber with Enhanced Moisture Stability

    Authors: , , , , - Angewandte Chemie 2014 cited by 1,987

  16. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 136

  17. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2002 cited by 442

  18. ATP Consumption by Sarcoplasmic Reticulum Ca2+ Pumps Accounts for 40-50% of Resting Metabolic Rate in Mouse Fast and Slow Twitch Skeletal Muscle

    Authors: , , , - PLoS ONE 2013 cited by 132

  19. Orchestrating and sharing large multimodal data for transparent and reproducible research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 26

  20. In Silico Predictive Modeling of CRISPR/Cas9 guide efficiency

    Authors: , , , - 2015 cited by 42

  21. Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy

    Authors: , , , , , , , , , - Cancer Research 2019 cited by 32

  22. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel

    Authors: - Journal of Clinical Oncology 2002 cited by 716

  23. Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2000 cited by 409

  24. A Taxon-Specific and High-Throughput Method for Measuring Ligand Binding to Nicotinic Acetylcholine Receptors

    Authors: , , , , , , , , , , , , , - Toxins 2019 cited by 40